Article
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.
Immunology - 1 Nov 2017
Boudousquie Caroline, Bossi Giovanna, Hurst Jacob M, Rygiel Karolina A, Jakobsen Bent K, Hassan Namir J
Abstract excerpt
The success of immune system-based cancer therapies depends on a broad immune response engaging a range of effector cells and mechanisms. Immune mobilizing monoclonal T cell receptors (TCRs) against cancer (ImmTAC™ molecules: fusion proteins consisting of a soluble, affinity enhanced TCR and an anti-CD3 scFv antibody) were previously shown to redirect CD8+ and CD4+ T cells against tumours. Here we present...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
